NCT06303167 2026-03-18Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)National Cancer Institute (NCI)Phase 2 Active not recruiting19 enrolled 10 charts